Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3B
pubmed:dateCreated
2005-9-14
pubmed:abstractText
Glucocorticoids are the most important group of drugs used in the treatment of childhood acute lymphoblastic leukemia (ALL), however, resistance to this group remains the main obstacle in curing the disease. One of the possibilities to circumvent glucocorticoid resistance is the use of new compounds, such as cortivazol (CVZ), which has two binding sites for the glucocorticoid receptor.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0250-7005
pubmed:author
pubmed:issnType
Print
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2253-8
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:articleTitle
Cytotoxicity of cortivazol in childhood acute lymphoblastic leukemia.
pubmed:affiliation
Department of Pediatric Hematology and Oncology, Ludwik Rydygier's Collegium Medicum of Bydgoszcz, Nicolaus Copernicus University of Torun, Poland. jan.styczynski@wp.pl
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't